Healthy adults
Conditions
Interventions
Study food will be ingested twice daily, for 2 weeks.
Placebo will be ingested twice daily, for 2 weeks.
Sponsors
IMEQRD Co., Ltd
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Age between 20 and 65 years at the time of informed consent 2.Japanese male or female 3.Those who have a fasting blood glucose level of less than 126 mg/dL at the time of screening. 4.Those who have an HbA1c value of less than 6.5% at the time of screening 5.Those who is able to have blood collected multiple times a day 6.BMI of less than 30 kg/m2 7.Those who are able to input electronic diary with smartphone / PC 8.Those who received sufficient explanation about the trial, volunteered to participate after understanding the purpose, and agree to participate in the trial with written consent
Exclusion criteria
Exclusion criteria: 1.Those who has been currently visiting a hospital or treated with any drug or herbal remedy (however, dosing as needed is allowed) for any disease 2.On diet / exercise therapy under the guidance of a doctor 3.Have a current or history of serious illness 4.Those who regularly uses any quasi-drug, food for specified health use, health food or supplement that is considered to affect glucose degradation and blood glucose level (however, the person will be eligible if he/she can stop using it during the study period after provision of the informed consent) 5.Current or history of drug allergies or food allergies 6.Those who have a current or a past medical history of drug or alcohol dependence 7.Those who work in shifts, or night shifts 8.Alcohol consumption of >60g equivalent 9.Those who have excessive smoking habits (21 or more cigarettes / day) 10.Planning to significantly change their lifestyle (diet, sleep, exercise, etc.) during the trial 11.Pregnant or lactating, or willing to be pregnant during the trial 12.Participation in another clinical trial within one month of enrollment into the trial, participating currently or planning to participate 13.Judged by the investigator to be unsuitable for participating in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood glucose area under the curve (AUC) | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in insulin level over time, Change in blood glucose level over time, Insulin area under the curve (AUC), Breath carbon dioxide content, Blood ethanol concentration, Body fat percentage, Abdominal circumference | — |
Countries
Japan
Contacts
Public ContactYoshitada Hira
IMEQRD Co., Ltd Planning and Sales Department
Outcome results
None listed